Navigation Links
Cobalis Corp. Announces Second Update Conference Call for Investors on October 5, 2010
Date:9/28/2010

IRVINE, Calif., Sept. 28 /PRNewswire-FirstCall/ -- Cobalis Corp. (Pink Sheets: CLSC) is holding the second Investor Update Conference Call to provide investors and shareholders with further details and the latest updates about a range of important securities, financial and legal issues.

Shareholders and investors MUST RSVP to participate in this conference call, to be held Tuesday, October 5, 2010 at 1:15pm Pacific Time. Interested parties may RSVP to participate in the call by contacting Cobalis at (949) 260-0123 between 9:00 am and 5:00 pm Pacific Time, Monday through Friday, to get the conference call dial-in number and passcode.

The agenda of this call will include: Financial status and private funding; details of current legal and corporate issues; update on the recent SEC complaint and resolution; resumption of trading; launch update; current legal settlements and how the Company is meeting the terms of its agreements; overview of additional revenue opportunities; what happened with previously planned product release dates.

There will also be a Question and Answer opportunity as well as opportunities following the Conference Call for one-on-one discussions with interested parties.

FORWARD LOOKING STATEMENTS

Cobalis Corp., expectation of results and other forward-looking statements contained in this email involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those expected are the following: business conditions and general economic conditions; competitive factors, such as pricing and marketing efforts; and the pace and success of product research and development. These and other factors may cause expectations to differ.

ABOUT COBALIS CORP—PREHISTIN®

Cobalis Corp. is a specialty pharmaceutical, nutraceutical and preventive healthcare product development and marketing company. Its flagship product, PreHistin® Allergy Defense Formula, The World's FIRST Pre-Histamine, is designed to mitigate overproduction of IgE levels and restore a normal response to seasonal and year-round indoor and outdoor allergens. PreHistin® is available without prescription for both long-term and daily use.

For PreHistin® product information and ordering please visit at www.PreHistin.com or call toll free 1-877-4POLLEN. For additional company information please visit the corporate website at www.Cobalis.com CONTACT:Chas Radovich, PresidentCobalis Corp.949-260-0123info@cobalis.com
'/>"/>

SOURCE Cobalis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cobalis Corp. Provides Marketing Update Conference Call for Investors
2. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
3. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
4. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
5. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
6. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
7. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
8. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
9. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
10. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
11. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... Manhattan New york (PRWEB) , ... April 28, ... ... is pleased to announce that Aditya Patel M.D. has joined the revolutionary endoscopic ... fellowship training and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt ...
(Date:4/28/2017)... Edinburg, Texas (PRWEB) , ... April 28, 2017 , ... ... a plaque in recently to the labor and delivery team at Women’s Hospital at ... generous mothers who give birth at the hospital and decide to donate. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... 28, 2017 , ... Bill Howe started his sewer and drain company in ... Howe joined the team, the Bill Howe brand was born and they began cultivating ... giving back to the San Diego community in which they worked, lived and were ...
Breaking Medicine News(10 mins):